Mounjaro 3 Pens: What a Three-Pen Supply Means for Your Treatment

What the trial evidence tells us about the twelve-week window

The SURMOUNT-1 trial, published in the New England Journal of Medicine, ran tirzepatide (Mounjaro) across 72 weeks, randomising 2,539 adults with obesity. One of its clearest findings is that meaningful weight reduction builds incrementally: the steepest early losses happen as doses escalate, and the plateau at any given strength tells the prescriber something important. A three-pen supply sits neatly inside that design. Twelve weeks at a single dose gives your body time to adjust, gives the medicine time to work at that level, and gives your clinical team enough data to make the next decision with confidence.

NICE's appraisal of tirzepatide — TA1026, published December 2024 — notes that if less than 5% weight loss has occurred after six months at the highest tolerated dose, the appropriateness of continuing should be reviewed. Three pens is half of that six-month window. It is not a diagnostic checkpoint on its own, but it is precisely the right length of time to bring to a clinical review with real observations: how nausea settled, what appetite changes feel like day to day, how injection sites are rotating across the different Mounjaro injection pens.

That review rhythm is why the three-pen structure exists. It is not arbitrary.

Dose increases and what happens between three-pen supplies

Mounjaro is licensed in the UK at six strengths: 2.5, 5, 7.5, 10, 12.5 and 15 mg. The 2.5 mg starting pen exists to settle your system rather than to produce significant weight loss, its job in the first four weeks is tolerability. After that, increases are typically planned in four-weekly steps, which is why if you are exploring what a Mounjaro 2 pens supply looks like, it can sit neatly within a transitional period before a planned move upward.

A prescriber deciding whether to increase your dose at the twelve-week mark will generally want to see evidence that you have been using the treatment as directed. At nume, that means a clinical re-review before every repeat order, a real prescriber reads your responses, not a form router. You can read more about how Mounjaro injections work and what the titration schedule looks like in practice on our detailed injection guide.

If you are thinking about what the ongoing cost looks like across dose tiers, our Mounjaro price comparison page sets out the UK private market context honestly, including what to look for beyond the headline figure.

Practical considerations for managing three pens at home

Twelve weeks of pens take up more fridge space than a single box. Keep them in the original packaging, refrigerated between 2 and 8 °C, away from the freezer compartment. The Patient Information Leaflet, which the NHS tirzepatide page also signposts, gives the precise room-temperature window for any pen you have taken out of the fridge, follow that, not online summaries, because the figure can vary by product batch and formulation update.

It is worth thinking ahead about timing. If your twelve-week supply lands just before a bank holiday weekend or a family holiday, plan your injection days so you are not caught mid-week without access to your pen. Monday orders placed before 12 pm at nume are dispatched the same day and arrive by DPD the next working day, which makes it straightforward to time re-orders around real life rather than scrambling at the last minute.

Each pen is a single-use device: once the four doses are administered, dispose of it safely. A sharps container keeps used pens secure until your local pharmacy or council collection service can take them. Changing the needle before each injection is equally important for comfort and to maintain the pen's mechanism, and our guide to needles for Mounjaro pens covers needle compatibility and technique in full.

Is a three-pen supply right for where you are in treatment?

Not every patient is at a stage where three pens at one strength makes sense. Someone in the first weeks of treatment may be reviewed sooner; someone stable on a maintenance dose may have a different repeat cadence depending on their prescriber's assessment. The number of pens supplied is always a clinical call.

Private treatment through a regulated pharmacy like ours sits outside the NHS waiting list, with no referral needed. Eligibility for Mounjaro is based on BMI and health history: the licence covers adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related condition such as high blood pressure, high cholesterol or type 2 diabetes. Lower BMI thresholds can apply for some ethnic backgrounds under UK guidance. BMI alone does not guarantee a prescription, the prescriber weighs the full picture at consultation.

If you are wondering which supply option fits your current point in treatment, our broader Mounjaro pens guide explains the different supply formats available, and you can explore the full range of weight-loss treatment options at nume to understand the wider clinical landscape. When you are ready, checking your eligibility takes a few minutes and costs nothing.